Brief: Vbi Vaccines Announces Dosing Of First Patients In Phase 2B Study Of Vbi-1901 In Recurrent Gbm
07/09/2023 15:56
VBI Vaccines Inc VBIV.O :
* VBI VACCINES ANNOUNCES DOSING OF FIRST PATIENTS IN PHASE
2B
STUDY OF VBI-1901 IN RECURRENT GBM
* VBI VACCINES- FDA GRANTED FAST TRACK DESIGNATION, ORPHAN
DRUG
DESIGNATION TO VBI-1901 IN RECURRENT SETTING, FOLLOWING PHASE
1/2A STUDY RESULTS
* VBI VACCINES INC- INTERIM DATA ANALYSIS EXPECTED MID-YEAR
2024,
SUBJECT TO SPEED OF ENROLLMENT
Source text for Eikon: ID:nBw1PN4V6a
Further company coverage: VBIV.O
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55